Intervention Review

You have free access to this content

Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage

  1. Gina Westhoff1,*,
  2. Amanda M Cotter2,3,
  3. Jorge E Tolosa3,4

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 30 OCT 2013

Assessed as up-to-date: 24 JUN 2013

DOI: 10.1002/14651858.CD001808.pub2


How to Cite

Westhoff G, Cotter AM, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD001808. DOI: 10.1002/14651858.CD001808.pub2.

Author Information

  1. 1

    Stanford University and University of California-San Francisco, Stanford, CA, USA

  2. 2

    University of Limerick, Department of Obstetrics and Gynaecology, Limerick, Ireland

  3. 3

    Global Network for Perinatal and Reproductive Health, Portland, OR, USA

  4. 4

    Oregon Health and Science University, Department of Obstetrics and Gynecology, Portland, Oregon, USA

*Gina Westhoff, Stanford University and University of California-San Francisco, 300 Pasteur Dr. HH333, Stanford, CA, 94305-5317, USA. ginaw@stanford.edu. ginawesthoff@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 30 OCT 2013

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Oxytocin versus no uterotonics, Outcome 1 PPH (clinically estimated blood loss > or = 500 mL).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Oxytocin versus no uterotonics, Outcome 2 Therapeutic uterotonics.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Oxytocin versus no uterotonics, Outcome 3 Severe PPH (clinically estimated blood loss > or = 1000 mL).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Oxytocin versus no uterotonics, Outcome 4 Mean blood loss (mL).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Oxytocin versus no uterotonics, Outcome 5 Maternal haemoglobin concentration (Hb) < 9 g/dL 24 to 48 hours postpartum.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Oxytocin versus no uterotonics, Outcome 6 Blood transfusion.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Oxytocin versus no uterotonics, Outcome 7 Third stage greater than 30 minutes.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Oxytocin versus no uterotonics, Outcome 8 Mean length of third stage (minutes).
[Analysis 1.9]
Analysis 1.9. Comparison 1 Oxytocin versus no uterotonics, Outcome 9 Manual removal of the placenta.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Oxytocin versus no uterotonics, Outcome 12 Nausea between delivery of the baby and discharge from the labour ward.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Oxytocin versus no uterotonics--subgroup analyses, Outcome 1 PPH (clinically estimated blood loss > or = 500 mL); randomised v. quasi-randomised trials.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Oxytocin versus no uterotonics--subgroup analyses, Outcome 2 PPH (clinically estimated blood loss > or = 500 mL); active v. expectant management.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Oxytocin versus no uterotonics--subgroup analyses, Outcome 3 PPH (clinically estimated blood loss > or = 500 mL); IM v. IV oxytocin.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Oxytocin versus no uterotonics--subgroup analyses, Outcome 4 PPH (clinically estimated blood loss > 500 mL); oxytocin dose < 10 IU v. 10 IU.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Oxytocin versus no uterotonics--subgroup analyses, Outcome 5 Therapeutic uterotonics; randomised v. quasi-randomised trials.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Oxytocin versus no uterotonics--subgroup analyses, Outcome 6 Therapeutic uterotonics; active v. expectant management.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Oxytocin versus no uterotonics--subgroup analyses, Outcome 7 Therapeutic uterotonics; IM v. IV oxytocin.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Oxytocin versus no uterotonics--subgroup analyses, Outcome 8 Therapeutic uterotonics; oxytocin dose < 10 IU v. 10 IU.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 1 PPH (clinically estimated blood loss > or = 500 mL).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 2 Therapeutic uterotonics.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 3 Severe PPH (clinically estimated blood loss > or = 1000 mL).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 4 Mean blood loss (mL).
[Analysis 3.6]
Analysis 3.6. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 6 Blood transfusion.
[Analysis 3.8]
Analysis 3.8. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 8 Mean length of third stage (minutes).
[Analysis 3.9]
Analysis 3.9. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 9 Manual removal of the placenta.
[Analysis 3.10]
Analysis 3.10. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 10 Diastolic blood pressure > 100 mm Hg between delivery of the baby and discharge from the labour ward.
[Analysis 3.11]
Analysis 3.11. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 11 Vomiting between delivery of the baby and discharge from the labour ward.
[Analysis 3.12]
Analysis 3.12. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 12 Nausea between delivery of the baby and discharge from the labour ward.
[Analysis 3.13]
Analysis 3.13. Comparison 3 Oxytocin versus ergot alkaloids, Outcome 13 Headaches between delivery of the baby and discharge from the labour ward.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 1 PPH (clinically estimated blood loss > or = 500 mL); randomised v. quasi-randomised trials.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 2 PPH (clinically estimated blood loss > or = 500 mL); active v. expectant management.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 3 PPH (clinically estimated blood loss > or = 500 mL); IM v. IV oxytocin.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 4 PPH (clinically estimated blood loss > 500 mL); oxytocin dose < 10 IU v. 10 IU.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 5 Therapeutic uterotonics; randomised v. quasi-randomised trials.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 6 Therapeutic uterotonics; active v. expectant management.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 7 Therapeutic uterotonics; IM v. IV oxytocin.
[Analysis 4.8]
Analysis 4.8. Comparison 4 Oxytocin versus ergot alkaloids--subgroup analyses, Outcome 8 Therapeutic uterotonics; oxytocin dose < 10 IU v. 10 IU.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 1 PPH (clinically estimated blood loss > or = 500 mL).
[Analysis 5.3]
Analysis 5.3. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 3 Severe PPH (clinically estimated blood loss > or = 1000 mL).
[Analysis 5.4]
Analysis 5.4. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 4 Mean blood loss (mL).
[Analysis 5.6]
Analysis 5.6. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 6 Blood transfusion.
[Analysis 5.8]
Analysis 5.8. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 8 Mean length of the third stage (minutes).
[Analysis 5.9]
Analysis 5.9. Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 9 Manual removal of the placenta.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Oxytocin + ergometrine versus ergot alkaloids--subgroup analyses, Outcome 1 PPH (clinically estimated blood loss > or = 500 mL); randomised v. quasi-randomised trials.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Oxytocin + ergometrine versus ergot alkaloids--subgroup analyses, Outcome 2 PPH (clinically estimated blood loss > or = 500 mL); active v. expectant management.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Oxytocin + ergometrine versus ergot alkaloids--subgroup analyses, Outcome 3 PPH (clinically estimated blood loss > or = 500 mL); IM v. IV oxytocin.